CSF3 and non-small cell lung carcinoma: The DRAGON study,17 a multicenter, prospective, single‐arm, phase II trial of RAM+DOC with primary prophylactic PEG‐G‐CSF support for chemotherapy‐naive older patients with advanced NSCLC is ongoing in Japan.